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The incretin hormones, glucagon-like peptide-1 (GLP-1) and its receptor agonist (exendin-4), are well known for glucose
homeostasis, insulinotropic eﬀect, and eﬀects on weight loss and food intake. However, due to the rapid degradation of GLP-1
by dipeptidylpeptidase-IV (DPP-IV) enzyme and renal elimination of exendin-4, their clinical applications have been restricted.
Although exendin-4 has longer half-life than GLP-1, it still requires frequent injections to maintain eﬃcacy for the treatment of
diabetes. In recent decades, various polymeric delivery systems have been developed for the delivery of GLP-1 and exendin-4 genes
or peptides for their long-term action and the extra production in ectopic tissues. Herein, we discuss the modiﬁcation of the
expression cassettes and peptides for long-term production and secretion of the native peptides. In addition, the characteristics
of nonviral or viral system used for a delivery of a modiﬁed GLP-1 or exendin-4 are described. Furthermore, recent eﬀorts to
improve the biological half-life of GLP-1 or exendin-4 peptide via chemical conjugation with various smart polymers via chemical
conjugation compared with native peptide are discussed.
1.Introduction
Diabetes is classiﬁed into two types, depending on the
insulin production in body [1] .O n ei st y p e1d i a b e t e s ,
which type 1 diabetes accounts for 5% to 10% of all
diabetes cases in the USA. In type 1 diabetics, insulin is not
produced, due to destruction of the pancreatic β-cells, by
autoimmune response. The other is type 2 diabetes and this
constitutes 90% to 95% in all diabetes cases. The features
of type 2 diabetes are characterized by insulin resistance,
hyperglucagonaemia, pancreatic β-cell dysfunction, and
abnormally high rate of β-cell apoptosis [2, 3]. For the
treatment of diabetes, incretin hormones such as glucagon-
likepeptide-1(GLP-1)andGLP-1receptoragonist(exendin-
4) have been investigated because they act in opposition
against the characterizations of diabetes [4]. There are a
large number of papers reviewed with respect to action and
eﬀects of GLP-1 and exendin-4 action of eﬀects [5–7].
The biological function of GLP-1 is well known as an
incretin hormone released from gastrointestinal L-cells [1,
3]. Native GLP-1 (1–37) is produced two active circulat-
ing forms, GLP-1 (7–37) and GLP-1 (7–36) amide [6]
(Figure 1). GLP-1 (7–36) amide is more abundant in blood.
Incretin eﬀect of GLP-1 is reviewed in several papers [2,
3, 6]. Intact GLP-1 promotes insulin secretion, inhibits
glucagon secretion in pancreas, and increases the synthesis
of proinsulin. Furthermore, GLP-1 promotes proliferation
of pancreatic islet β-cell, inhibits β-cell apoptosis, delays in
gastric emptying, and induces weight loss by suppression of
appetite in type 2 diabetes [2, 5]. GLP-1, also, enhances the
hepatic glucose uptake due to increasing glycogen syntheses
activity [8]. Although GLP-1 has many advantages, however,
its application in clinical trials is considerably restricted
because GLP-1 is degraded rapidly by dipeptidyl-peptidase
(DPP-IV), along with renal clearance [9]. Accordingly, long-
acting GLP-1 receptor agonists such as exendin-4, which are
more resistant to degradation by DPP-IV, may have a long
term therapeutic eﬃcacy compared with GLP-1 [2].
GLP-1 receptor agonist, exendin-4, is an exocrine hor-
mone isolated from the parotid gland of the Gila monster2 ISRN Endocrinology
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Figure 1: Amino acid sequence of GLP-1 and exendin-4. GLP-1 consists of two active circulating forms, GLP-1 (7–36) amide and GLP-1
(7–37).
lizard. Exendin-4 has, also, been shown to inhibit glucagon
secretion, reduce glucose clearance, stimulate insulin secre-
tion,protectagainstβ-cellapoptosis,promoteβ-cellprolifer-
ation, promote satiety, and inhibit gastric emptying [10, 11].
It was reported that exendin-4 binds to GLP-1 receptor, since
exendin-4hasa53%aminoacidsequencehomologyofGLP-
1[ 12]( Figure 1). According to report that GLP-1 receptors
aredetectedinmultiplecellswithintheimmunesystem[13],
GLP-1orexendin-4collectivelysuggeststhatcurrentincretin
therapiesmayhavemultiplebeneﬁcialeﬀectsinpatientswith
type 1 diabetes, including improved glycemic control via
multiple mechanisms. Furthermore, exendin-4 was also used
as a target moiety for in vivo pancreatic islet imaging [14].
In addition, the GLP-1 receptors are present on various
tissues [6]. It is also expressed in cardiac myocytes [15].
Preclinical and clinical studies have shown that GLP-1 and
exendin-4 are strongly linked to salutary cardiovascular
eﬀects [16, 17]. This supports the facts that cardiovascular
and cerebrovascular diseases account for around 65% of
mortality among patients with diabetes [18–20]. Several
studies demonstrated that the symptoms of cardiovascular
diseases were improved during treatment with GLP-1 or
exendin-4 therapy and that GLP-1 protected heart against
cardiac remodeling after myocardial infarction [18, 21, 22].
Indeed, GLP-1 receptor in the brain mediates not only the
prevention of neuronal degeneration by GLP-1, but the
enhancement of central nervous system cell survival and
function by exendin-4 [10].
In spite of these advantages of GLP-1 or exenedin-4,
however, its clinical trials are still restricted because GLP-
1 has very short in vivo half-life (<2min). In addition,
administration of exendin-4, which has longer half-life
than GLP-1 produced anti-exendin-4 antibodies, resulting
in the appearance of diminished glycemic response and the
requirement of readministration [3].
New strategies should be developed for an eﬀective long-
term action of GLP-1 or exendin-4. Several approaches
have been undertaken to develop agents that replicate
or replace the actions of GLP-1. Some of them are in
various stages of clinical development [23, 24]. One way
among several innovative methods is to deliver exogenous
incretinhormonegenesorpeptidesusingpolymericcarriers.
Currently, delivery carriers are classiﬁed two parts: non-viral
and viral system. Nonviral vector using liposomes, naked
DNA, and synthetic polymers has many advantages such as
low cytotoxicity, low immunogenicity, and unlimited size for
transgene. On the other hand, viral vectors using viruses
has advantages such as high and stable intracellular delivery.
With respect to these delivery carriers, it will be introduced
in below each section.
In this paper, we will describe with a focus on intriguing
vector designs, potentials of the techniques for long-lasting
action, ectopic production, and secretion of GLP-1 or
exendin-4 via a variety of polymers, which are classiﬁed
with characteristics using nonviral system, viral system, and
modiﬁed peptides based on polymeric delivery.
2. Deliveryand TherapeuticSystems on
Effects of GLP-1 andIts Agonist
Current approaches for the delivery of GLP-1 and exendin-
4 for higher and longer therapeutic eﬀects will be discussed
with the introduction of various polymers. One approach is
to deliver the DNA coding GLP-1 or exendin-4. The DNA
will produce therapeutic proteins for a prolonged time, sug-
gesting that gene delivery may overcome shortcomings of the
peptide delivery. Another approach is to modify the peptides
with polymers to inhibit or reduce enzymatic degradation of
the peptides.ISRN Endocrinology 3
2.1. NonViral Delivery Carriers for Gene Expression System.
N o n V i r a l lg e n ed e l i v e r yc a r r i e r sh a v es o m ea d v a n t a g e s
compared with viral gene delivery carriers, such as lower
immunogenicity, highly reproduction, and a simple quality
control process, excellent safety proﬁle, and ability to carry
large amounts of DNA [25]. One part among a variety
of nonVirall carriers including liposomes and polymers is
to exploit the natural ability of cationic polymer. Cationic
polymers condense plasmid DNA (pDNA) by electrostatic
interaction, forming polyplexes [26]. In this section, current
incretin gene expression systems and polymeric carriers for
the incretin genes expression systems are discussed (Table 1).
2.1.1. Poly(ethylenimine) (PEI). PEI has high charge density,
composed of 25% primary amines, 50% secondary amines,
and25%tertiaryamines [27].Ithasbeenshowntoeﬀectively
condense pDNA into colloidal particles that eﬀectively
transfect DNA into a variety of cells both in vitro and in
vivo.C u r r e n t l y ,b r a n c h e d2 5k D aP E Ih a sb e e nw i d e l yu s e d
for gene delivery due to transfection eﬃciency and lower
cytotoxicity than higher molecular weight PEI [28, 29].
PEI has been used for delivery of the GLP-1 constructs.
The ﬁrst GLP-1 plasmid was composed of the modiﬁed
GLP-1 cDNA with furin cleavage site. The transcrip-
tion of the GLP-1 cDNA was driven by chicken β-actin
enhancer/promoter (pβ-GLP-1), which has been known
as one of the strongest mammalian promoters [30]. The
ﬁrst two amino acids are the receptor binding site. For
the translation initiation, the ﬁrst codon for the GLP-
1 cDNA was methionine. However, the ﬁrst methionine
might interfere with the interaction between GLP-1 and its
receptor by masking the ﬁrst two amino acids. Therefore,
the methionine should be removed after translation for
full activity. In this approach, we designed the GLP-1
plasmid with furin recognition site. After translation, the
ﬁrstmethionine, codedbytheinitiation codon, wasremoved
in Golgi apparatus, producing wild-type GLP-1. In vitro
transfection into HepG2 cells and coculture assays with rat
islets showed that the produced GLP-1 had insulinotropic
eﬀect. Zucker diabetic fatty (ZDF) rats were treated with
PEI/pβ-GLP-1 polyplex via intravenously single injection.
The results showed therapeutic eﬀects by increasing insulin
and reducing blood glucose levels for 2 weeks. However, the
therapeutic eﬀects were not enough to normalize the blood
glucose level.
To increase the therapeutic eﬀects of the GLP-1 gene
therapy, two approaches were employed. The ﬁrst was to
improve the expression plasmids by employing the NFκB
binding site. The modiﬁed GLP-1 plasmid vector (pSIGLP-
1/NFκB) with 5x nuclear factor κB( N F κB) binding sites
was constructed to enhance nuclear import of the plasmid
[31]. NFκB is a transcription factor, which is produced in
cytoplasm. Without any activation signal, NFκB resides in
cytoplasm as a complex with IκB. However, on activation,
NFκB translocates into the nucleus. The activation signals
include innate immune response such as activation of toll-
like receptors (TLRs) and tumor formation phobal esters.
However,withoutthesesignals,basallevelNFκBtranslocates
into the nucleus continuously. In this nuclear translocation
process, NFκB may recognize its binding sites of the GLP-1
expressionplasmidsandcotranslocateswiththeplasmidinto
the nucleus. Therefore, it may increase nuclear traﬃcking of
the transfected plasmid and gene expression. This approach
is not limited to GLP-1 gene therapy and may be useful
for various gene therapies. Diet-induced obese (DIO) mice
were treated with PEI/pSIGLP-1/NFκB complex. The results
showed that the blood glucose levels were decreased and
maintainedfor3weeks.Inaddition,theplasmainsulinlevels
increased in a similar way, while weight gain and food intake
were reduced.
Another approach to improve the GLP-1 expression
plasmid was to employ the two-step transcription ampliﬁ-
cation systems (TSTA). The ﬁrst TSTA system for the GLP-1
expressionwasconstructedandevaluatedinvitrobyLeeetal.
[32]. This system was composed of the two expression plas-
mids. In the ﬁrst plasmid, the Gal4-DNA binding domain
(DBD)/p65-transactivation domain (TAD) fusion protein
was expressed under the control of the chicken β-actin
enhancer/promoter. Then, the expressed Gal4-DBD/p65-
TAD protein binds to the upstream activating sequence
(UAS) in the second plasmid and then stimulated the
transcription of the GLP-1 gene. It is important to determine
the optimal ratio between ﬁrst and second plasmids for a
high expression of GLP-1. In their in vitro data, the TSTA
system induced the GLP-1 expression by 4-fold compared
with pβ-GLP-1 system. In this in vitro evaluation, the TSTA
system was delivered with PEI. For optimum expression, two
plasmidsshouldbedeliveredintoasamecell.Thecomplexof
PEI and the TSTA system may have more than one plasmid,
and some complexes might have both pβ-Gal4-p65 and
pUAS-GLP-1 for TSTA eﬀect. However, it is unlikely that all
complexes have two plasmids. Therefore, it may be useful to
construct the GLP-1 TSTA system in a plasmid, which has
both Gal4-p65 and UAS-GLP-1 expression units.
2.1.2. Arginine-Grafted Bioreducible Polymer (ABP). PEI has
signiﬁcant acute toxicity concerns such as cellular toxicity,
aggregation of erythrocytes, and entrapment in the lung
capillary[51],andtheapplicationofPEItoclinicalsettingsis
strictly limited. Therefore, a safe and eﬃcient carrier should
be developed for GLP-1 gene therapy. One of the important
approaches is to develop biodegradable gene carriers. There
are several examples of biodegradable gene carriers. For
example, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) is
a degradable gene carrier with ester bonds in its backbone.
PAGA was used for delivery of interleukin genes for diabetes
[52]o rc a n c e rg e n et h e r a p i e s[ 53]. PAGA was nontoxic
and did not induce any cytotoxicity in vitro and in vivo,
suggesting that biodegradability is one of the important
requirements for safe gene therapy. However, ester bonds in
PAGA were rapidly degraded in aqueous solution and PAGA
had relatively short half-life. Therefore, another approach
was employed for the development of biodegradable gene
carriers. Disulﬁde bonds are stable in extracellular space,
while they are rapidly degraded in reduction condition in
cytoplasm. Therefore, the carrier with disulﬁde bonds forms4 ISRN Endocrinology
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stablecomplexwithpDNAoutsideofcellsbutreleasespDNA
rapidly inside of cells after entry to cells. According to this
approach, arginine-grafted bioreducible polymer (ABP) was
synthesized and evaluated as a gene carrier for the GLP-
1 gene. ABP had higher transfection eﬃciency than PEI in
various types of cells and tissues in vitro and in vivo and did
not induce any signiﬁcant toxicity to cells [33, 54–57].
ABP was evaluated for delivery of a novel TSTA-GLP-
1 expression system with the secretion signal peptide (SP).
The TSTA-GLP-1 expression system based with SP was
constructed by insertion of SP at the upstream of the GLP-1
cDNA of pUAS-GLP-1 [58]. Therefore, the TSTA system was
composed of pβ-Gal4-p65 and pUAS-SP-GLP-1. The TSTA-
GLP-1 system with SP (TSTA-SP-GLP-1) was complexed
with ABP and then delivered into cells in vitro.T h e
ABP/TSTA-SP-GLP-1 polyplex increased the GLP-1 expres-
sion levels and improved the insulin secretion-inducing
ability in vitro. In vivo study may be required for fully identi-
ﬁcation of the eﬀects of TSTA-SP-GLP-1 with ABP polymer.
The most eﬃcacies among our previous results about the
treatmentofdiabeteswereshowedinexperimentofexendin-
4 expressed by TSTA system with secretion signal sequence
(unpublished data). In this study, TSTA-SP-exendin-4 with
ABP polymer (ABP/TSTA-SP-exendin-4) led to the antidi-
abetic eﬃcacies for 12 days without hypoglycemia in DIO
mice.
2.1.3. Chitosan. Chitosan is safe, nontoxic, cationic, and bi-
odegradable polysaccharides, composed of D-glucosamine
and N-acetyl-glucosamine [26, 34, 59]. Chitosan was ﬁrst
usedasacarrierforthedeliveryGLP-1geneforthetreatment
of diabetes by Jean et al. [60]. In this study, they con-
structed a GLP-1 plasmid (pVax1-GLP-1) which contained a
furin recognition site to ensure posttranslational processing
bearing an N-terminal histidine residue (His7)i np V a x 1
vector for eﬀective gene expression. This approach using the
furin recognition site was exactly the same as the previous
approach to remove the initiation methionine from the
produced GLP-1 peptide. The expression of GLP-1 was
driven by the cytomegalovirus immediate early (CMV IE)
promoter and enhancer. The therapeutic eﬀect of the most
eﬀective chitosan-based complex (chitosan 92-10-5; degree
of deacetylation or DDA-MW in kDa-chitosan/DNA N:P
ratio) containing pVax1-GLP-1 was examined by two routes
of 7 times administration, intramuscular (i.m.), and sub-
cutaneous (s.c.), at days 0, 7, 14, 21, 35, 49, and 63 in the
ZDF rat. The highest plasma GLP-1 levels were observed in
mice treated with chitosan/pVax1-GLP-1 complex compared
with those of pVax1-GLP-1 via both s.c. and i.m. in 14 days
after ﬁnal treatment (day 77). At the same time, insulin
levels increased more than 2-fold compared with that of
uncomplexed plasmid. This increase in the insulin level
coincided with a sustained GLP-1 expression in plasma.
Mice treated with chitosan/pVax1-GLP-1 complex, also,
induced a reduction in food intake and body weight gain. In
conclusion,theincretineﬀectsofpVax1-GLP-1withchitosan
maintained for 14 days following the last injection. However,
the CMV promoter and enhancer have silencing eﬀect. The
methylated CpG motifs induce innate immune response and
increase the secretion of proinﬂammatory cytokines [61].
The increased cytokines may result in the hypermethylation
of the CMV promoter and enhancer, decreasing promoter
activity. Therefore, the mammalian promoters such as β-
actin promoter may be a better selection than the CMV
promoter.
2.1.4. Intramuscular Injection and Electroporation of Naked
Chimeric GLP-1/IgG-Fc Plasmid. Electroporation is a widely
used technique for the transfection of DNA in vitro and in
vivo. This can, also, be used to introduce DNA into muscle,
skin, liver, and cancer cells as well as to control localization
of transgene expression by DNA injection site [35].
Kumar et al. constructed a plasmid that expressed a
fusion protein of human GLP-1 and mouse IgG heavy chain
constant region with the Ig κ secretion leader peptide [62].
Conjugation of IgG-Fc region prolongs circulation time of
many peptide drugs [63, 64]. The expressed GLP-1/IgG-Fc
fusion protein showed that it was capable of activating GLP-
1R via the cAMP induction and stimulating insulin secretion
from islet β-cells in a glucose-dependent manner in vitro.I n
the results to examine in vivo eﬀect of GLP-1/IgG-Fc protein,
diabetic db/db mice were intramuscularly injected twice
(2 weeks interval after ﬁrst administration) with GLP-1-
IgG-Fc/VRnew or IgG-Fc/VRnew (control vector) plasmids,
and then the muscles were electroporated using electrodes.
Although the in vivo eﬀects of GLP-1/IgG-Fc fusion protein
on lowering blood glucose levels was not interestingly
diﬀerent between the two groups of mice, the fasting blood
glucose levels were shown 1.7-fold lower than the control
mice at 12 weeks after ﬁrst injection. Moreover, the fasting
insulin and glucagon levels showed about 1.6-fold-enhanced
insulin secretion and 1.3-fold-reduced glucagon release in
mice treated with GLP-1/IgG-Fc plasmid compared with the
IgG-Fc-treated control mice. This result showed that GLP-
1/IgG-Fcsystemcouldapplylong-lasting eﬀectsof GLP-1for
the treatment of diabetes.
2.2. Viral Delivery Carriers for Gene Expression System. Viral
v e c t o r sh a v eb e e nu s e dt od e l i v e rt h eG L P - 1g e n et ot a r g e t
cells. Viral vectors have high levels of cellular transfection,
highintracellulardeliverybyeasyescapefromtheendosome,
nuclear import, and transcriptional stability, compared with
nonvirallvectorsystem[55,57,65].Inthispart,wedescribed
about GLP-1 or its mimetic gene delivery using viral vectors
including adenovirus (Ad) or adeno-associated virus (AAV)
(Table 2).
2.2.1. GLP-1 and Exendin-4 Gene Delivery Using Adenovirus.
Adenovirus is one of the most potent gene delivery vectors
used in gene therapy. Also, Ad has widely been used for
clinical application, due to their advantages. First, they are
produced with high titer and high transduction eﬃciency in
dividing and nondividing cells. Second, they do not induce
the mutagenesis by insertion of their genome into the host
DNA. Furthermore, their biological characteristics of virus
are well known [66, 67]. It is, however, well known that6 ISRN Endocrinology
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they are accumulated in the liver and induce immune system
after systemic administration [36, 65, 68]. Many GLP-1
delivery studies using Ad have been performed with various
expression cassette designs of GLP-1 gene rather than vector
itself modiﬁcation for long-term expression and secretion of
active GLP-1 in ectopic tissues.
Parsons and colleagues incorporated a novel GLP-1 ex-
pression cassette in adenoviral gene to express exogenous
GLP-1 [69]. They constructed the GLP-1 mini-gene mutated
with Ala at position 8 to Gly. The CMV enhancer and
ubiquitin promoter were used for the GLP-1 expression.
The exendin-4 leader sequence was located at the upstream
of the GLP-1 gene for secretion of GLP-1 after expression
(pCUbiEX4GLP-1Gly8). The CUbi vector with the CMV
enhancer and ubiquitin promoter is well known for directing
expression for more than 1 month in the liver [37]. In-
jection of Ad (Ad-CUbiEX4GLP-1Gly8) containing this
GLP-1 expression cassette showed the improved glucose
homeostasis after single intravenous (i.v.) injection of 1 ×
1010 or 1 × 1012 viral particles (VP) of Ad in db/db mice or
ZDF rats, respectively. These euglycemic eﬀects maintained
for 6 weeks of the study, whereas plasma insulin levels
showed no signiﬁcant diﬀerence between control groups.
Another GLP-1 expression system using adenoviral vec-
tor was constructed by Jun’s group [70]. They used ex-
pression system contained CMV promoter, β-globin/IgG
chimeric intron, the GLP-1 cDNA, and albumin leader
sequence. In their ﬁrst report, streptozotocin- (STZ-) in-
duced nonobese diabetic/severe combined immunodeﬁ-
ciency (NOD/SCID) mice or spontaneously diabetic NOD
mice were intravenously injected one time with 6 × 1011 VP
or 1 × 1012 VP of Ad-GLP-1, respectively. NOD/SCID mice
treated with Ad-CMV-GLP-1 showed normoglycemia for
30 days postadministration, while serum insulin levels were
observed higher in mice treated with Ad-GLP-1 compared
with mice treated with control Ad. In addition, NOD mice
treated with CFA, which prevent autoimmune response
agent β-cell, and Ad-CMV-GLP-1 maintained lowering
blood glucose levels for 1 year due to the inhibition of
autoimmune attack of regenerated β-cell. In another study,
single administration of Ad-CMV-GLP-1 in ob/ob mice
resulted in antidiabetic eﬀects such as the improvement
of β-cell function, reduction of gluconeogenesis, and the
improvement of insulin sensitivity [38].
Antidiabetic eﬀects of exendin-4 expressed by Ad were
reported by Samson and colleagues [39]. They used a helper-
dependent adenovirus (HDAd) vector with exendin-4 driven
by the CMV promoter. The vector also contains a leader
sequence for enhanced secretion and the furin cleavage for
production of wild-type exendin-4. Single injection (i.v.)
of HDAd-CMV-exendin-4 (1 × 1011 VP) in diet-induced
obesity (DIO) reduced the blood glucose levels and hepatic
lipid. Exendin-4 was expressed for 15 weeks but did not
induce the plasma insulin level, suggesting that the enhanced
expression of exendin-4 may improve the insulin sensitivity.
In another study with Ad, Lee et al. constructed a GLP-1
expression vector with the CMV promoter and the insulin
leader sequence followed by GLP-1 [71]. This expression
cassettewasincorporatedinAdorAAVvector(Ad-IL-GLP-1
or AAV-IL-GLP-1). The results suggest that the expression of
GLP-1 induced insulin in dose- or glucose-dependent man-
ner in vitro. In vivo animal study showed that administration
of Ad-IL-GLP-1 achieved longed-glucose homeostasis and
improvedinsulinsensitivityinZDFratstreatedwith2 ×1012
VP for 21 days.
Delivery of the GLP-1 or exendin-4 gene using viral vec-
tors showed promising results of the applications of genes to
diabetes. Disadvantage of Ad such as liver accumulation can
rather work as an advantage for the production of incretin
in hepatocyte. However, side-eﬀects and toxicity of viral
vectors may still have limited their application to clinics.
Currently,viralvectorsareusefulforproof-of-conceptrather
thanforclinicalapplications.Itismoreimportanttodevelop
nontoxic viral vectors with little side-eﬀects.
2.2.2. GLP-1 Gene Delivery Using Adeno-Associated Virus.
Unlike Ad, AAV is capable of integration into the human
genome at a speciﬁc site on chromosome-19 [72, 73]a n d
infectious to nondividing cells. In addition, it does not
induce immune response of transduced cells, due to lack of
viral genes. Therefore, AAV can achieve eﬃcient and long-
term gene transfer in a variety of tissues [40]. Especially,
continuous and long-term control of insulin and glucose
level is important. Unlike episomal vectors, AAV has higher
rate of integration of their DNA into the host cell chro-
mosome. However, the integration rate is not as high as
retroviralvectorsandfurtherimprovementoftheintegration
rate may be beneﬁcial for this purpose. Although there are
integration hotspots in the human genome for AAV, some
integration may induce oncological recombination of the
genes. Therefore, integration of the viral genome into the
host chromosome should be carefully controlled.
For the treatment of type 1 diabetes, AAV-MIP-GLP-
1 produced GLP-1 gene by the mouse insulin-II promoter
(MIP). MIP conﬁned the gene expression speciﬁcally in
pancreatic β-cells in a glucose-dependent manner. The pro-
glucagon signal sequence was used for the facilitated secre-
tionofthepeptide[41].Inthisstudy,i.p.injectionof1 ×1012
VP of AAV containing GLP-1 expression cassette increased
the β-cell proliferation and maintained glucose homeostasis
in the STZ-induced type 1 diabetes mice.
Recently, another study showed that normal glucose level
was maintained for 4 months after portal-vein injection (1
× 1012 VP) of double-strand (ds) AAV containing a GLP-1
plasmid (dsAAV-CB-GLP-1)in db/db obesemice,suggesting
that administration route may be an important factor for the
success of the gene therapy. In this study, GLP-1 expression
cassette in dsAAV was constructed with the CMV enhancer
and chicken β-actin promoter (CB promoter), Ig κ-chain
leader sequence, and a furin protease recognition sequence
[42].
2.3. Peptide Delivery of Modiﬁed GLP-1 or Exendin-4 with
Polymers. Although GLP-1 or GLP-1 receptor agonist have
many incretin eﬀects for diabetes, its short half-life in vivo
still remain a question to overcome. Consequently, delivery8 ISRN Endocrinology
of GLP-1 peptide in vivo has been focused on maintaining
long-acting antidiabetic eﬀects as well as resistance to degra-
dation by DPP-IV enzyme. In order to maintain long-acting
activity of peptide from degradation by DPP-IV enzyme,
severalkindsofpolymershavebeenusedwithmodiﬁedGLP-
1 or exendin-4 peptide (Table 3).
2.3.1. Sustained Release by Encapsulation of
GLP-1 or Exendin-4
(1) Controlled Release of GLP-1 Peptide Using Triblock
CopolymerofPLGA-PEG-PLGA(ReGel). Long-termdelivery
of active GLP-1 is required for the treatment of diabetes by
peptide delivery. Therefore, controlled release of GLP-1 from
ad e p o ti sad e s i r a b l ea p p r o a c h .A B A - t y p et r i b l o c kc o p o l y -
mer, poly[(DL-lactide-co-glycolide)-b-ethylene glycol-b-
(DL-lactide-coglycolide)] (PLGA-PEG-PLGA; ReGel), was
used as a depot for controlled release of GLP-1 [43]. Regel is
biodegradable gel in aqueous solution and performed sol-gel
transitiondependingontemperature.Therefore,themixture
of GLP-1 and ReGel at room temperature was injected into
animal model subcutaneously. At the body temperature,
Regel formed gel immediately after injection and released
GLP-1 gradually. ReGel released GLP-1 for over 14 days in
ZDF rates after subcutaneous injection. Moreover, normal
blood glucose level was maintained in rats injected with
ZnGLP-1/ReGel compared with that of control rats for more
than 14 days. Therefore, ReGel is a convenient and useful
carrier for the GLP-1 peptide. ReGel formulation technique
mayprovidenormalizationofbloodglucoselevelsbycontrol
of loaded amount of GLP-1 and gel concentration [74].
(2) Microencapsulation of GLP-1/Polymer Conjugate and Rat
Islets. For long-term therapeutic eﬀect of GLP-1, poly(N-
vinylpyrrolidone-co-acrylic acid-g-PEG) (VAP-) conjugated
GLP-1 (VAPG), was microencapsulated in alginate with rat
islets [44]. Zinc complexation of GLP-1 (GLP-1/Zn2+)w a s
used as control of VAPG [75]. An in vitro study showed
that microencapsulated islets with VAPG induced higher
insulin secretion in a glucose-dependent manner, compared
with the control group. Microencapsulated islets with VAPG,
also, maintained the insulin secretion for 5 weeks, indicating
that VAPG was eﬃcient in promoting the functionality of
encapsulated islets for a prolonged time. This prolonged
eﬀect of encapsulated islets may be due to antiapoptotic
eﬀect and β-cell proliferation eﬀect of GLP1. This system
could be reloaded with fresh islets and each component,
suggestingthatitwouldbeservedasapotentialtoolforlong-
term insulinotropic eﬀect via adjustment of implanted islets.
(3) Exendin-4 Inhalation Delivery System Adsorbed to Porous
Large PLGA Microspheres. Although exendin-4 has many
therapeutic beneﬁts for diabetes, its half-life is still short
to fully treat diabetes mellitus. To induce sustained release
and extended in vivo half-life exendin-4, modiﬁed exendin-
4 adsorbed to improved porouspoly(lactic-co-glycolic acid)
(PLGA) microparticle was produced by Kim et al., for
antidiabetic inhalation [76]. PLGA-based biodegradable
microparticles have been investigated for sustained and
targeted/localized delivery of agents such as puriﬁed protein,
bacteria, DNA, or viruses [26, 77].
In this study, exendin-4 was modiﬁed with the sixteen
carbons of palmitic acid (palmityl-acylated exendin-4; Ex4-
C16) for strong adsorption onto the hydrophobic surfaces of
porous PLGA microspheres because of inducing the rapid
release of therapeutic drugs by considerable empty volume,
thin matrix frame of porous PLGA. Palmityl acylation to
induce binding to human serum albumin, also, helps release
of exendin-4 from PLGA microparticle to extend half-life
of exendin-4. Adsorption onto and release from porous
PLGA microparticle were conﬁrmed by ﬂuorescent dye
conjugated to Ex4-C16. Specially, for the pulmonary delivery,
the porous PLGA microparticle was directly administered
into the lungs via trachea of mice. In the evaluation
of the pulmonary hypoglycemic eﬃcacy, glucose level in
PLGA/Ex4-C16-treated mice was 2.6-fold lower than those
of porous PLGA for the whole experimental time (150h).
This glucoregulatory eﬀect continued until 5 days after the
administration. Therefore, porous PLGA microparticle via
inhalation delivery has pharmaceutical potential using lung
deposition for antidiabetic peptides.
2.3.2. PEGylation and Albumin Conjugates of
GLP-1 or Exendin-4
(1) PEGylation of GLP-1. Polyethylene glycol (PEG) is an
uncharged, hydrophilic, widely used polymer. PEGylation
can reduce protein-protein interaction, resulting in circula-
tion time of therapeutic proteins [26, 45]. PEGylation of a
protein extends in vivo pharmacokinetics by increasing the
clearance time in the blood, decreases proteolytic degrada-
tion, and reduces immune response [78].
Biological activity of PEGylated GLP-1 was ﬁrst inves-
tivated by Lee et al. [79]. The PEGylation sites were with
site-speciﬁc PEG2k conjugation at position His7 in N-
terminal by andaldehyde monomethoxypoly-PEG (mPEG-
N-GLP-1) and Lys26/Lys34 in C-terminal by succinimidyl
propionate monomethoxypoly-PEG (mPEG-Lys-GLP-1). In
this study, PEGylated GLP-1 had the prolonged half-life and
the improved proteolytic stability against DPP-IV enzyme,
compared with native GLP-1. mPEG-Lys-GLP-1 increased
insulin secretion more eﬃciently than mPEG-N-GLP-1 in
rat pancreatic islets. This may be due to steric hindrance
of mPEG-N-GLP-1. N-terminal amino acids of GLP-1 are
the receptor binding sites and PEGylation of N-terminus
may interfere with the interaction of the GLP-1 peptide
and its receptor. Furthermore, mPEG-Lys-GLP-1 showed
the improved plasma exposure and the stability, compared
with native GLP-1 following s.c. or i.v. administration in
Rats, suggesting the PEGylation eﬀect. Actual antidiabetic
eﬃcacies of PEG-Lys-GLP-1 were assessed in db/db mice.
The results showed that the administration of mPEG-Lys-
GLP-1 reduced the blood glucose and increased the insulin
levels [46].
Another example is PEGylated dual-acting peptide for
diabetes (PEG-DAPD). Hjorth et al. reported that chimericISRN Endocrinology 9
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peptide consisting of the N-terminal of glucagon and the C-
terminal of GLP-1 was recognized by both receptors with
high aﬃnity [47]. However, functional activity was not
reported at that time. Recently, this dual-acting peptide for
diabetes (DAPD) of GLP-1 receptor agonist and glucagon
receptor antagonist was produced. This DAPD was reported
to activate the GLP-1 receptor and inhibit the glucagon
receptor [48]. Several site mutations were incorporated into
the DAPD for enhanced therapeutic eﬀects. PEGylation
of DAPD was performed with 22 or 43kDa PEG to
overcome the short half-life of the peptides. PEG-PAPD
was administrated into the rat models subcutaneously. The
intraperitoneal glucose tolerance test (IPGTT) showed that
PEG-DAPD reduced the blood glucose level, compared with
control.
(2) GLP-1-Albumin Conjugate (CJC-1131). As one of
approaches to overcome the short half-life of GLP-1, Kim
et al. modiﬁed the GLP-1 peptide with a single amino acid
substitution of L-Ala8 to D-Ala8 at position 2 and a Lys37
addition to the C-terminus with selective attachment of a [2-
[2-[2-maleimidopropionamido-(ethoxy)ethoxy]acetamide
to the epsilon amino group of Lys37 [49]. The COOH-
terminal end of this modiﬁed GLP-1 was conjugated to
a short covalent reactive chemical linker and coupled to
the speciﬁc cysteine residue in the albumin molecule for
long half-life. This peptide was complexed with CJC-1131,
producing the GLP-1-albumin drug aﬃnity complex (DAC).
For the evaluation of therapeutic eﬀects, albumin/CJC-1131
was injected via various routes (i.p., s.c., or i.v.) in db/db
mice following glucose loading. The results showed that
i.p. injection of albumin/CJC-1131 reduced the glycemic
excursion more eﬃciently, compared with that of s.c. injec-
tion. Intravenous CJC-1131 administration, also, produced
a dose-dependent reduction in glycemic excursion following
glucose loading. The prolonged repeated administration
of albumin/CJC-1131 conjugate twice daily for 4 weeks
reduced the fed blood glucose levels eﬀectively compared
with injection of saline. Albumin/CJC-1131 conjugate also
stimulated islet cell proliferation and increased proinsulin
mRNA transcripts, although an increase of plasma insulin
was not observed in conjugate-treated mice.
(3) Exendin-4 Conjugated with Human Serum Albumin via
Hetero-Bifunctional PEG Linkage. Compared with the direct
conjugation to albumin, the conjugation of peptide and
albumin was performed to exendin-4 with spacer of PEG
by Kim’s group. They reported that exendin-4 and albumin
conjugates with longer PEG spacer increased the receptor
binding aﬃnity of exendin-4. This eﬀect may be due to
that the longer spacer the conjugates had, the less steric
hindrance they had [50]. As long-space linker, a 5kDa PEG
was used for the conjugation of human serum albumin
(HAS) and exendin-4. Finally, HAS-PEG-exendind-4 made
viachemicalconjugationshowed24.6-or1.97-foldincreased
receptor binding aﬃnity than Ex4 or HAS-exendin-4 in
cell, respectively. Pharmacokinetics of HSA-PEG-exendin-
4 in mice showed that PEG linker prolonged the half-life
(24.4h) compared with exendin-4 only (2.1h) or HAS-
exendin-4 (11.4h) following i.p. administration. PEG linker
also induced better hypoglycemic eﬀects and prolonged
duration compared with that of HSA-exendin-4 without a
PEG linker in nonfasted diabetic mice. The results suggest
that HAS-PEG-exendin-4 may be useful for treatment for
type 2 diabetes with long-term duration of eﬀect.
2.3.3. GLP-1 or Exendin-4 Analogs Containing Disulﬁde Bond.
Recently, Li’s group introduced a modiﬁed GLP-1 peptide
containing disulﬁde bond in wild-type GLP-1 for the
treatment of type 2 diabetes. The presence of disulﬁde bonds
in structure was suggested as an ideal tool to improve the
stability of therapeutic peptide or protein. First, they con-
structed a modiﬁed GLP-1 homodimer by single mutation
to cystein at position 10, 23, or 33 of wild-type GLP-1 [80].
As a result, among GLP-1 analogs, analog (hdGLP1G10C)
mutated at position 10 of GLP-1 was the most biological
active form, compared with native GLP-1. The rats treated
with hdGLP1G10C showed an increased insulin secretion in
180min following glucose loading. The hdGLP1G10C also
showed long-acting glucoregulatory eﬀects for 5 days by
single-dose injection glucose tolerance in rats. In addition,
ZDF rats treated with hdGLP1G10C had improved the dia-
betic condition, compared with GLP-1 after subcutaneously
administration every 5 days during 35 days.
Li et al. also mutated GLP-1 or exendin-1 analogs with
additional cysteine residue based on similar manner as
described above. In addition, several glycine residues were
attached at C-terminal tail to protect against the degradation
by DPP-IV enzyme [81]. The most eﬀective analog among
the tested GLP-1 and exendin-4 analogs was GLP17057. The
analog reduced the glucose levels, increased insulin levels,
and showed long-lasting eﬀects in rats, compared with wild-
type GLP-1 or exendin-4. Therefore, interdisulﬁde bonds
between GLP-1 would be a useful tool for improving the
stability and therapeutic eﬀects.
3. Conclusion
Incretin such as GLP-1 and exendin-4 has been the most
important peptide drugs in diabetes research. There is no
doubt that GLP-1 and its mimetric are attractive therapeutic
materials for the diabetes treatment. However, short half-
life has limited their application to clinics. Therefore, many
research eﬀorts have been made to overcome these problems.
The approaches can be summarized into 4 categories. First,
prolonged therapeutic eﬀects are achieved by gene delivery
with strong tissue-speciﬁc expression cassette to induce high
production of incretin. However, the most diﬃcultbarrierin
gene delivery is to develop an eﬃcient and safe carrier. To
date, polymeric and viral vectors have been tested for eval-
uation of gene therapy approaches. Although viral vectors
had high eﬃciency in transduction, the intrinsic problems
of viral vectors such as oncogenesis and immunogenesis
have strictly limited their application to GLP-1 gene therapy.
Due to the slow progression of diabetes, toxic carriers such
as viral vectors will not be used for GLP-1 diabetes geneISRN Endocrinology 11
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Figure 2: Potentiation therapy based on incretin for the treatment of diabetes.
t h e r a p ya sc u r r e n tf o r m s .I n s t e a d ,p o l y m e r i cv e c t o r sh a v e
some advantages, compared with viral vectors. Currently,
the transfection eﬃciency of polymeric carriers may not be
enough for clinical application. However, their safety proﬁle
suggests that active research in this ﬁeld may produce a
useful carrier in a near future. The second approach is to
use hydrogel or microsphere as a depot for controlled release
of GLP-1. The stability of GLP-1 in the depot should be
conﬁrmed and the safety should be proved. In terms of
safety, ReGel and PLGA microspheres have been evaluated
in preclinical and clinical trials, suggesting their applications
in clinics in future. The third approach is to modify for
protection of the GLP-1 peptide from the degradation by
enzymes. PEGylation, albumin conjugation, or the insertion
of disulﬁde bond have been evaluated. The modiﬁcation
increased the half-life as well as solubility and stability of
the peptide. The last approach is to use with inhibitors
against DPP-IV. Some inhibitors are commercially available
for clinical use. It has the ability to inactivate DPP-IV,
resulting in the prolonged half-life and activity of produced
incretin hormones. However, DPP-IV itself cannot directly
cause normoglycemia with no eﬀect on gastric emptying
and the improvement to complications. Also, it should be
considered the durability and eﬃcacy for the treatment of
diabetes. In contrast to DPP-IV inhibitors, the described
approaches have high eﬃcacy and lots of incretin eﬀects
via single administration than DPP-IV inhibitors. However,
to apply in clinical ﬁeld, these systems must be considered
safety, stability, and more long-lasting action to appear the
therapeutic eﬀects with no toxicity in patient. Therefore, by
combining the complementary characteristics of approaches
mentioned in this paper and DPP-IV inhibitors, it should be
possible to overcome the limitations associated with each.
In trade of recent decade based on above-mentioned
strategies, most studies have been focused on improvement
of the pharmacokinetics of GLP-1 or exendin-4. However,
besides the induction of exogenous incretins, eﬀorts to
increaseendogenousGLP-1productionareneededtobepar-
allel for the treatment of diabetes such as a-glycosidase
inhibitor [6, 82]o rm i g l i t o l[ 83].
At this point, more investigations remained to be ex-
plored. For example, it is that activator, inhibitor, or siRNA
capable of activation or inactivation of action mechanism of
GLP-1 and its receptor or target of another kind of receptor
such as GLP-2 receptor. At the same time, the sensitivity of
these treatments to patients has to be considered for per-
sonalized diagnosis and therapy due to the diﬀerence against
GLP-1receptorresponsivenessandsensitivityineachperson.
Finally, diabetic treatment will need combination therapy
with other existing treatment to induce an increase of both
endogenous and exogenous incretin hormones for suﬃcient
therapeutic eﬃcacies (Figure 2). In this sense, polymeric-
based on incretin approaches may serve as intriguing tools to
generate more therapeutic GLP-1 or exendin-4 for diabetes.
Withalltheseeﬀorts,therapeuticapplicationsofincretinwill
be realized as the positive impact with little side-eﬀects in a
near future.
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